Results from both trials showed patients receiving Dulera experienced significant improvement from baseline in lung function (mean area under the concentration-time curve for forced expiratory volume in 1 second, measured from 0 to 12 hours [FEV1 AUC0-12h]) at week 12 compared to mometasone furoate (Trial 1 and 2) and placebo (Trial 1). In Trial 1, these differences were maintained through week 26. Additionally, a significantly greater increase in the mean trough FEV1 was observed for Dulera 100mcg/5mcg compared to formoterol 5mcg as well as to placebo in Trial 1. In Trial 2, a greater numerical increase in the mean trough FEV1 was observed for Dulera 200mcg/5mcg compared to Dulera 100mcg/5mcg and mometasone furoate 200mcg.
Dulera is a pressurized metered-dose inhaler with a built-in numeric counter that shows the number of remaining doses. Dulera is expected to be available by the end of July 2010 in mometasone furoate/formoterol fumarate 100mcg/5mcg and 200mcg/5mcg dosage strengths.
For more information call (800) 444-2080 or visit www.merck.com.